MA53138A - Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) - Google Patents

Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)

Info

Publication number
MA53138A
MA53138A MA053138A MA53138A MA53138A MA 53138 A MA53138 A MA 53138A MA 053138 A MA053138 A MA 053138A MA 53138 A MA53138 A MA 53138A MA 53138 A MA53138 A MA 53138A
Authority
MA
Morocco
Prior art keywords
ikzf2
oxoisoindoline
piperidine
finger
hydroxy
Prior art date
Application number
MA053138A
Other languages
English (en)
Other versions
MA53138B1 (fr
Inventor
Claire Adcock
Simone Bonazzi
Artiom Cernijenko
Philip Lam
Kathryn Taylor Linkens
Hasnain Ahmed Malik
Noel Marie-France Thomsen
Michael Scott Visser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2019/055804 external-priority patent/WO2020012334A1/fr
Publication of MA53138A publication Critical patent/MA53138A/fr
Publication of MA53138B1 publication Critical patent/MA53138B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA53138A 2018-07-10 2019-07-08 Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) MA53138B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695920P 2018-07-10 2018-07-10
PCT/IB2019/055804 WO2020012334A1 (fr) 2018-07-10 2019-07-08 Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)

Publications (2)

Publication Number Publication Date
MA53138A true MA53138A (fr) 2021-05-19
MA53138B1 MA53138B1 (fr) 2023-10-31

Family

ID=75905122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53138A MA53138B1 (fr) 2018-07-10 2019-07-08 Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)

Country Status (2)

Country Link
AR (1) AR116110A1 (fr)
MA (1) MA53138B1 (fr)

Also Published As

Publication number Publication date
AR116110A1 (es) 2021-03-31
MA53138B1 (fr) 2023-10-31

Similar Documents

Publication Publication Date Title
IL278951A (en) History of 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-6,2-dione and their use in the treatment of IKZF2-dependent diseases
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49458A (fr) Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
MA56392A (fr) Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies
MA50417A (fr) Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA52575A (fr) Pansement pour le traitement de la peau endommagée
MA55604A (fr) Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA44935A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA53817A (fr) Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv
MA53739A (fr) Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?